Author:
Rigato M.,Avogaro A.,Fadini G. P.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference23 articles.
1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364–1379. doi: 10.2337/dc12-0413
2. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H, Wilken M, Agerso H (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43(9):1664–1669 (jm9909645)
3. European Medicines Agency Victoza 6 mg/ml solution for injection in pre-filled pen. http://www.medicinesorguk/EMC/medicine/21986/SPC/Victoza+6+mg+ml+solution+for+injection+in+pre-filled+pen . Accessed on 4 May 2015
4. Food and Drug Administration (2010) Victoza® [liraglutide (rDNA origin) injection], solution for subcutaneous use. https://www.accessdatafdagov/drugsatfda_docs/label/2010/022341lblpdf . Last accessed on 4 May 2015
5. Rigato M, Fadini GP (2014) Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 7:107–120. doi: 10.2147/DMSO.S37644
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献